MRKMerck Sharp & Dohme LLCSigning up patients
A Clinical Trial of MK-2010 Alone and With Other Treatments in Participants With Advanced Solid Tumors (MK-2010-002)
Malignant Neoplam · Advanced Solid Tumors
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 480 (planned)
- Started
- Oct 21, 2026
- Main results expected
- Sep 26, 2028
- Fully finished
- Jul 28, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Number of Participants with Adverse Events (AEs)
Measured over: Up to approximately 24 months
Number of Participants Who Discontinue Study Treatment Due to an AE
Measured over: Up to approximately 24 months
Number of Participants Who Experience Dose-Limiting Toxicity (DLT)
Measured over: Up to approximately 28 days
Objective Response Rate (ORR)
Measured over: Up to approximately 24 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07793942 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC